{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T03:18:40Z","timestamp":1778987920154,"version":"3.51.4"},"reference-count":40,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T00:00:00Z","timestamp":1753574400000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017170","name":"Thailand Science Research and Innovation","doi-asserted-by":"publisher","award":["FRB680102\/0162"],"award-info":[{"award-number":["FRB680102\/0162"]}],"id":[{"id":"10.13039\/501100017170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,7,1]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Evaluating skin reactions is crucial in topical product development. Turmeric\/epigallocatechin-3-gallate (EGCG) emulgel demonstrates therapeutic potential for cutaneous diseases, warranting further investigation in human studies. The Human Repeat Insult Patch Test (HRIPT) of skin irritation and sensitisation potential caused by the turmeric\/EGCG emulgel is designed to evaluate the safety of the investigational product in healthy volunteers prior to conducting the efficacy study in patients with dermatological diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>60 healthy Thai volunteers will be enrolled in this single-centre, double-blind HRIPT pilot clinical trial to evaluate skin irritation and sensitisation potential caused by turmeric\/EGCG emulgel. Primary endpoints include the number and proportion of participants exhibiting skin irritation and sensitisation, while secondary endpoints focus on the frequency and severity of adverse events. The study will comprise a screening period, a 3-week induction phase, a 2-week rest phase and a 1-week challenge phase. Fully occlusive adhesive patches containing study products will be applied to participants\u2019 backs 10 times. Skin irritation will be assessed using the Draize dermal irritation scoring system, and skin sensitisation will be evaluated using the International Contact Dermatitis Research Group scoring system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The Research Ethics Committee of the Faculty of Medicine, Chiang Mai University, approved this study protocol and related documents on 6 March 2025 (Ref. No. 108\/2025).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>TCTR20250317007.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-103571","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T10:35:28Z","timestamp":1753698928000},"page":"e103571","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Skin evaluation of turmeric\/epigallocatechin-3-gallate emulgel for skin irritation and sensitisation effects in healthy Thai participants (TULIP): a protocol for a randomised, double-blind, placebo-controlled trial"],"prefix":"10.1136","volume":"15","author":[{"given":"Kankanit","family":"Yeerong","sequence":"first","affiliation":[{"name":"Clinical Research Center for Food and Herbal Product Trials and Development (CR-FAH), Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"},{"name":"Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chadarat","family":"Ampasavate","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5961-8978","authenticated-orcid":false,"given":"Ajaree","family":"Rayanakorn","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mati","family":"Chuamanochan","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Napatra","family":"Tovanabutra","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4240-5367","authenticated-orcid":false,"given":"Mingkwan","family":"Na Takuathung","sequence":"additional","affiliation":[{"name":"Clinical Research Center for Food and Herbal Product Trials and Development (CR-FAH), Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"},{"name":"Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4649-597X","authenticated-orcid":false,"given":"Nut","family":"Koonrungsesomboon","sequence":"additional","affiliation":[{"name":"Clinical Research Center for Food and Herbal Product Trials and Development (CR-FAH), Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"},{"name":"Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"2025121509202400000_15.7.e103571.1","unstructured":"Litchman G , Nair PA , Atwater AR , et al . Contact dermatitis. Treasure Island (FL): StatPearls Publishing, 2023."},{"key":"2025121509202400000_15.7.e103571.2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yrtph.2007.10.019","article-title":"A review of critical factors in the conduct and interpretation of the human repeat insult patch test","volume":"52","author":"McNamee","year":"2008","journal-title":"Regul Toxicol Pharmacol"},{"key":"2025121509202400000_15.7.e103571.3","doi-asserted-by":"crossref","first-page":"104867","DOI":"10.1016\/j.yrtph.2021.104867","article-title":"Draize human repeat insult patch test (HRIPT): Seven decades of pitfalls and progress","volume":"121","author":"Bormann","year":"2021","journal-title":"Regul Toxicol Pharmacol"},{"key":"2025121509202400000_15.7.e103571.4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/15569520902938032","article-title":"The human repeated insult patch test in the 21st century: A commentary","volume":"28","author":"Basketter","year":"2009","journal-title":"Cutan Ocul Toxicol"},{"key":"2025121509202400000_15.7.e103571.5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13048-023-01120-6","article-title":"Curcumin: a natural organic component that plays a multi-faceted role in ovarian cancer","volume":"16","author":"Liu","year":"2023","journal-title":"J Ovarian Res"},{"key":"2025121509202400000_15.7.e103571.6","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1002\/jsfa.11372","article-title":"Curcumin, the active substance of turmeric: its effects on health and ways to improve its bioavailability","volume":"101","author":"Abd El-Hack","year":"2021","journal-title":"J Sci Food Agric"},{"key":"2025121509202400000_15.7.e103571.7","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14584"},{"key":"2025121509202400000_15.7.e103571.8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000535100","article-title":"Clinical studies on topical curcumin","volume":"36","author":"Di Lorenzo","year":"2024","journal-title":"Skin Pharmacol Physiol"},{"key":"2025121509202400000_15.7.e103571.9","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3889\/oamjms.2018.055","article-title":"Use of curcumin in psoriasis","volume":"6","author":"Di Nardo","year":"2018","journal-title":"Open Access Maced J Med Sci"},{"key":"2025121509202400000_15.7.e103571.10","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3390\/pharmaceutics16030412","article-title":"Natural stabilizers and nanostructured lipid carrier entrapment for photosensitive compounds, curcumin and capsaicin","volume":"16","author":"Jandang","year":"2024","journal-title":"Pharmaceutics"},{"key":"2025121509202400000_15.7.e103571.11","doi-asserted-by":"publisher","DOI":"10.1007\/s10863-018-9777-5"},{"key":"2025121509202400000_15.7.e103571.12","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27096"},{"key":"2025121509202400000_15.7.e103571.13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ijpharm.2017.04.068","article-title":"Potential and future scope of nanoemulgel formulation for topical delivery of lipophilic drugs","volume":"526","author":"Sengupta","year":"2017","journal-title":"Int J Pharm"},{"key":"2025121509202400000_15.7.e103571.14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2174\/1574891X14666190717111531","article-title":"Nano-emulgel: emerging as a smarter topical lipidic emulsion-based nanocarrier for skin healthcare applications","volume":"14","author":"Anand","year":"2019","journal-title":"Recent Pat Antiinfect Drug Discov"},{"key":"2025121509202400000_15.7.e103571.15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2174\/1381612826666191226100241","article-title":"Nanoemulgel: a promising phase in drug delivery","volume":"26","author":"Aithal","year":"2020","journal-title":"Curr Pharm Des"},{"key":"2025121509202400000_15.7.e103571.16","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) . ICH E6(R3): good clinical practice (GCP). Available: https:\/\/database.ich.org\/sites\/default\/files\/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf [Accessed 15 Mar 2025]."},{"key":"2025121509202400000_15.7.e103571.17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jama.2024.21972","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human participants","volume":"333","year":"2025","journal-title":"JAMA"},{"key":"2025121509202400000_15.7.e103571.18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/jid.1945.18","article-title":"Certain statistical considerations in patch testing","volume":"6","author":"Henderson","year":"1945","journal-title":"J Invest Dermatol"},{"key":"2025121509202400000_15.7.e103571.19","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3390\/biom14070776","article-title":"Skin rejuvenation efficacy and safety evaluation of Kaempferia parviflora standardized extract (BG100) in human 3D skin models and clinical trial","volume":"14","author":"Klinngam","year":"2024","journal-title":"Biomolecules"},{"key":"2025121509202400000_15.7.e103571.20","doi-asserted-by":"crossref","first-page":"350","DOI":"10.18203\/issn.2455-4529.IntJResDermatol20191761","article-title":"Study of the clinical pattern of contact dermatitis over the face and its correlation with patch testing","volume":"5","author":"Goel","year":"2019","journal-title":"Int J Res Dermatol"},{"key":"2025121509202400000_15.7.e103571.21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4236\/jcdsa.2019.93017","article-title":"Evaluation of the skin irritation and sensitization potential of the Cussons Baby Sensicare skin range of products in healthy volunteers","volume":"09","author":"Mulyanti","year":"2019","journal-title":"JCDSA"},{"key":"2025121509202400000_15.7.e103571.22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.yrtph.2007.11.004","article-title":"The Research Institute for Fragrance Materials\u2019 human repeated insult patch test protocol","volume":"52","author":"Politano","year":"2008","journal-title":"Regul Toxicol Pharmacol"},{"key":"2025121509202400000_15.7.e103571.23","unstructured":"U.S. Food and Drug Administration . Assessing the irritation and sensitization potential of transdermal and topical delivery systems for andas: draft guidance for industry. 2023. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/assessing-irritation-and-sensitization-potential-transdermal-and-topical-delivery-systems-andas [Accessed 15 Mar 2025]."},{"key":"2025121509202400000_15.7.e103571.24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/jocd.12535","article-title":"Absence of human skin irritation and allergenic potential after repeated patch applications of a lamellar moisturizer","volume":"18","author":"Nisbet","year":"2019","journal-title":"J Cosmet Dermatol"},{"key":"2025121509202400000_15.7.e103571.25","first-page":"123","article-title":"Patch test methods. I. A comparative study of six different types of patch tests","volume":"45","author":"Magnusson","year":"1965","journal-title":"Acta Derm Venereol"},{"key":"2025121509202400000_15.7.e103571.26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1034\/j.1600-0536.2000.042005251.x","article-title":"The importance of exposure estimation in the assessment of skin sensitization risk","volume":"42","author":"Robinson","year":"2000","journal-title":"Contact Derm"},{"key":"2025121509202400000_15.7.e103571.27","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12259184"},{"key":"2025121509202400000_15.7.e103571.28","first-page":"257","article-title":"Patch test methods. II. Regional variations of patch test responses","volume":"45","author":"Magnusson","year":"1965","journal-title":"Acta Derm Venereol"},{"key":"2025121509202400000_15.7.e103571.29","unstructured":"Guy RH , Maibach HI . Topical absorption of dermatological products. Boca Raton (FL): CRC Press, 2002."},{"key":"2025121509202400000_15.7.e103571.30","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/15569527.2012.684418","article-title":"Towards a perfect vehicle(s) for diagnostic patch testing: an overview","volume":"32","author":"Chiang","year":"2013","journal-title":"Cutan Ocul Toxicol"},{"key":"2025121509202400000_15.7.e103571.31","first-page":"91","article-title":"Alternate vehicles for diagnostic patch testing: an update","volume":"143","author":"Cyran","year":"2008","journal-title":"G Ital Dermatol Venereol"},{"key":"2025121509202400000_15.7.e103571.32","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0536.1992.tb03280.x","article-title":"Influence of area of application of allergen on sensitization in contact dermatitis","volume":"27","author":"Upadhye","year":"1992","journal-title":"Contact Derm"},{"key":"2025121509202400000_15.7.e103571.33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.31524\/bkkmedj.2020.11.005","article-title":"Evaluation of Potential Skin Sensitization of Humans Receiving Bright and Firm Hybrid Emulsion I","volume":"16","author":"Bunman","year":"2020","journal-title":"Bkkmedj"},{"key":"2025121509202400000_15.7.e103571.34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09546634.2023.2220446","article-title":"Dermal sensitization, safety, and tolerability of triple-combination clindamycin phosphate 1.2%\/benzoyl peroxide 3.1%\/adapalene 0.15% gel from three clinical trials","volume":"34","author":"Draelos","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"2025121509202400000_15.7.e103571.35","first-page":"119","article-title":"Skin irritation and sensitization potential of fixed-dose combination of diclofenac 1% and menthol 3% topical gel: results of two phase I patch studies","volume":"67","author":"Liu","year":"2017","journal-title":"Drug Res (Stuttg)"},{"key":"2025121509202400000_15.7.e103571.36","first-page":"722","article-title":"Dermal toxicity","volume":"10","author":"Draize","year":"1955","journal-title":"Food Drug Cosmet Law J"},{"key":"2025121509202400000_15.7.e103571.37","unstructured":"Draize JH . Appraisal of the safety of chemicals in foods, drugs, and cosmetics. Austin (TX): The Association of Food and Drug Officials of the United States, 1959."},{"key":"2025121509202400000_15.7.e103571.38","first-page":"39406","article-title":"Guideline for the study and evaluation of gender differences in the clinical evaluation of drugs; notice","volume":"58","author":"Administration","year":"1993","journal-title":"Fed Regis"},{"key":"2025121509202400000_15.7.e103571.39","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1600-0536.1977.tb03698.x","article-title":"Allergic contact dermatitis: Sex differences","volume":"3","author":"Leyden","year":"1977","journal-title":"Contact Derm"},{"key":"2025121509202400000_15.7.e103571.40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0536.1999.tb06229.x","article-title":"Population differences in skin structure and physiology and the susceptibility to irritant and allergic contact dermatitis: implications for skin safety testing and risk assessment","volume":"41","author":"Robinson","year":"1999","journal-title":"Contact Derm"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-103571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:20:36Z","timestamp":1765819236000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-103571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,28]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjopen-2025-103571"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-103571","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}